



**T lymphocyte cyclooxygenase isotypes and the role of
T lymphocytes in modulating monocyte and
synoviocyte cyclooxygenase expression**

By

LISA KATRINA STAMP MBChB, FRACP

A thesis submitted to the University of Adelaide

— as requirement for the degree of

Doctor of Philosophy

Department of Medicine

University of Adelaide

And

Rheumatology Unit

Royal Adelaide Hospital

September 2003

TABLE OF CONTENTS

ABSTRACT	I
DECLARATION	III
PUBLICATIONS AND ABSTRACTS ARISING FROM THIS THESIS.....	IV
ACKNOWLEDGEMENTS.....	VII
ABBREVIATIONS	IX
CHAPTER 1 LITERATURE REVIEW	1
1.1 Introduction.....	1
1.2 Eicosanoid biosynthetic pathway.....	4
1.2.1 Phospholipase A ₂	6
1.2.2 Cyclooxygenase.....	9
1.2.3 Terminal eicosanoid synthases	25
1.3 Eicosanoid activities in monocytes and lymphocytes.....	28
1.3.1 Prostaglandin E ₂	30
1.3.2 Thromboxane A ₂	32
1.3.3 Prostaglandin D ₂	33
1.3.4 Prostacyclin.....	34
1.4 Eicosanoid receptors	35
1.4.1 Thromboxane receptor.....	37
1.4.2 Prostaglandin E ₂ receptors.....	38

1.5	Cytokines	39
1.5.1	Cytokines in rheumatoid arthritis	39
1.5.2	Interleukin-17	40
1.5.3	Interferon- γ	51
1.5.4	Tumour Necrosis Factor- α	54
1.5.5	Interleukin-1 β	57
1.6	Rheumatoid arthritis.....	59
1.6.1	Role of T cells in rheumatoid arthritis.....	59
1.7	Summary	75
AIMS.....		76
CHAPTER 2 MATERIALS AND METHODS		77
2.1	T cell isolation.....	77
2.1.1	Preparation of mononuclear cells	77
2.1.2	Preparation of nylon fibre wool columns	78
2.1.3	Isolation of T cells by passage through NFWC.....	80
2.2	T cell stimulation	80
2.2.1	T cell stimulation with immobilized anti-CD3 and soluble anti-CD28.....	81
2.2.2	T cell stimulation with superantigen.....	82
2.2.3	Inhibition of T cell activation by Cyclosporin A.....	83
2.3	T cell fixation	83
2.4	Monocyte isolation.....	84

2.4.1 Counter-current elutriation	84
2.4.2 Monocyte isolation	86
2.5 Monocyte stimulation	86
2.6 Determination of cyclooxygenase activity.....	87
2.7 Selective inhibition of COX-1 and COX-2.....	87
2.8 Determination of the effects of TXA ₂	88
2.9 T cell - monocyte co-culture	89
2.9.1 Neutralization of IL-17 and IFN- γ in the transwell system	89
2.10 Culture of fibroblast-like synoviocytes.....	91
2.10.1 Freezing synoviocytes	92
2.11 Synoviocyte stimulation.....	92
2.12 Synoviocyte - T cell co-culture	93
2.12.1 Neutralization of IL-17 and TNF- α in T cell-synoviocyte co-culture ...	94
2.13 Measurement of TXB ₂ , PGE ₂ , & 6-keto-PGF _{1α} by RIA	94
2.14 Measurement of PGD ₂	95
2.14.1 Production of PGD ₂ antibody.....	95
2.15 Western immunoblot.....	99
2.15.1 Protein extraction	99
2.15.2 Protein separation and transfer	99
2.15.3 Membrane probing for specific proteins	100
2.16 Fluorescence activated flow cytometry.....	101
2.16.1 Single labeling.....	104
2.16.2 Double labeling	105
2.16.3 Intracellular staining.....	105
2.16.4 Preparation of normal human serum	106

2.17	T cell proliferation – [³ H]-thymidine incorporation	106
2.18	Enzyme-linked immunosorbent assay	107
2.19	[³ H]-arachidonic acid release	108
2.20	Rat thoracic duct lymphocytes.....	109
2.20.1	Animals and induction of arthritis.....	109
2.20.2	Collection of thoracic duct lymph.....	109
2.21	Statistics	110

**CHAPTER 3 DEVELOPMENT OF T CELL ISOLATION PROTOCOL AND
VALIDATION OF T CELL PURITY..... 111**

3.1	Introduction.....	111
3.2	Results.....	112
3.2.1	Isolation of T cells by counter-current elutriation	112
3.2.2	Isolation of T cells by nylon fibre wool columns	114
3.2.3	Assessment of cell purity pre- and post-NFWC	116
3.2.4	Final T cell isolation protocol.....	117
3.2.5	Cell number and cell viability post NFWC	117
3.3	Discussion	118

**CHAPTER 4 CHARACTERIZATION OF EICOSANOID BIOSYNTHETIC
PATHWAYS IN T LYMPHOCYTES 119**

4.1	Introduction.....	119
4.2	Results.....	121
4.2.1	Effect of T cell stimulation on expression of CD69	121

4.2.2	Expression of COX-1 and COX-2 in T cells	124
4.2.3	Effect of superantigen on COX-1 and COX-2 expression in T cells	129
4.2.4	Production of eicosanoids by T cells: comparison with monocytes.....	131
4.2.5	Effect of selective COX-1 and COX-2 inhibition on T cell eicosanoid production	134
4.2.6	Role of contaminating platelets and monocytes in eicosanoid production attributed to T cells	137
4.2.7	Expression of terminal eicosanoid synthases by T cells.....	138
4.2.8	Expression of the thromboxane receptor by T cells	140
4.2.9	Expression of COX-1 and COX-2 in rat thoracic duct lymphocytes	140
4.2.10	Expression of thromboxane synthase in thoracic duct lymphocytes from normal and arthritic rats.....	142
4.2.11	Eicosanoid production by thoracic duct lymphocytes from normal and arthritic rats.....	144
4.3	Discussion	145

CHAPTER 5 MODULATION OF T LYMPHOCYTE FUNCTION BY

THROMBOXANE A₂

5.1	Introduction.....	153
5.2	Results.....	154
5.2.1	Effect of T cell stimulation on [³ H]-thymidine incorporation.....	154
5.2.2	Effect of thromboxane synthase inhibition on TXA ₂ and PGE ₂ production by T cells.....	156
5.2.3	Effect of TXA ₂ on T cell proliferation	158

5.2.4	Effect of exogenous arachidonic acid on T cell proliferation.....	161
5.2.5	Effect of TXA ₂ on cytokine production by T cells	163
5.2.6	Effect of TXA ₂ on CD25 expression.....	166
5.3	Discussion.....	168

**CHAPTER 6 UP-REGULATION OF MONOCYTE COX-2 EXPRESSION
AND CYTOKINE SECRETION THROUGH INTERACTIONS WITH T
LYMPHOCYTES..... 177**

6.1	Introduction.....	177
6.2	Results.....	179
6.2.1	Effect of T cell stimulation on monocyte COX-2 expression and eicosanoid production	179
6.2.2	Effect of T cell supernatants and fixed T cells on monocyte COX-2 expression	181
6.2.3	Production of potential soluble mediators by T cells	182
6.2.4	Effect of TXA ₂ on monocyte COX-2 expression.....	182
6.2.5	Effect of IFN- γ on monocyte COX-2 expression and eicosanoid production 184	
6.2.6	Effect of IL-17 on monocyte COX-2 expression and eicosanoid production 187	
6.2.7	Effect of T cell stimulation on monocyte cytokine production.....	189
6.2.8	Effect of IFN- γ on monocyte TNF- α production: role of eicosanoids....	193
6.2.9	Effect of IL-17 on monocyte cytokine production	195
6.3	Discussion.....	196

CHAPTER 7 UP-REGULATION OF SYNOVIOCYTE COX-2	
EXPRESSION AND EICOSANOID PRODUCTION THROUGH	
INTERACTIONS WITH T LYMPHOCYTES.....	206
7.1 Introduction.....	206
7.2 Results.....	208
7.2.1 Expression of COX-1 and COX-2 in synoviocytes.....	208
7.2.2 Characterization of eicosanoid production by synoviocytes	209
7.2.3 Effect of T cells on synoviocyte COX-2 expression and eicosanoid production.....	211
7.2.4 Effect of varying the T cell to synoviocyte ratio on synoviocyte COX-2 expression and eicosanoid production.....	213
7.2.5 Time course for release by T cells of factors that stimulate synoviocytes to express COX-2 and produce eicosanoids	213
7.2.6 Time course of synoviocyte COX-2 expression and eicosanoid production: comparison of IL-1 β with T cell supernatants.....	216
7.2.7 Effect of IL-17 on synoviocyte COX-2 expression and eicosanoid production.....	218
7.2.8 Effect of T cell derived TNF- α on synoviocyte COX-2 expression and eicosanoid production.....	222
7.2.9 Effect of IL-17 in combination with TNF- α or IL-1 β on synoviocyte COX-2 expression and eicosanoid production.....	224
7.2.10 Effect of IFN- γ on synoviocyte COX-2 expression and eicosanoid production.....	226
7.2.11 Effect of TXA ₂ on synoviocyte COX-2 expression.....	226
7.3 Discussion.....	228

CHAPTER 8 SUMMARY	235
8.1 Introduction.....	235
8.2 Salient findings	235
8.3 Future directions	237
8.3.1 Role of TXA ₂ in T cell function and rheumatoid arthritis.....	237
8.3.2 Role of interleukin-17 in rheumatoid arthritis.....	238
 APPENDIX SOLUTIONS AND REAGENTS	 242
Solutions for flow cytometry	242
Solutions for elutriation	243
Solutions for radioimmunoassay.....	244
Solutions for ELISA.....	246
Solutions for Western Immunoblot.....	247
 REFERENCES.....	 254

ABSTRACT

Rheumatoid arthritis is a common inflammatory condition associated with joint destruction and disability. T lymphocytes, monocytes, and synoviocytes present within the inflamed joint all contribute to the inflammatory response by production of lipid mediators (eicosanoids) and peptide mediators (cytokines).

Interleukin-17 is a relatively recently described pro-inflammatory T cell derived cytokine which has been shown to induce monocyte and synoviocyte cytokine production. In comparison to other T cell cytokines, such as interferon- γ , it is found in abundant levels in rheumatoid synovial tissue and fluid. T cells have also been shown to induce monocyte and synoviocyte cytokine production through direct cell-cell contact. Through these mechanisms T cells may contribute to the perpetuation of inflammation in rheumatoid arthritis.

The eicosanoids, prostaglandin E₂ and thromboxane A₂, which are formed via the cyclooxygenase pathway, also have a role in promoting inflammation. To date most work has concentrated on monocyte eicosanoid production and the effects of monocyte derived prostaglandin E₂ on T cell functions. Furthermore, there has been a view that T cells do not contain cyclooxygenase and are therefore unable to produce eicosanoids. The recognition that cyclooxygenase exists in both a constitutive form (cyclooxygenase-1) and an inducible form (cyclooxygenase-2) has renewed interest in cyclooxygenase in all cell types.

The aim of this thesis was to examine cyclooxygenase isotypes in T cells and to characterize eicosanoid production by each isotype. The ability of T cells to contribute to the inflammatory response via up-regulation of cyclooxygenase-2 in other cell types was also examined.

The data presented in this thesis indicate that T cells contain cyclooxygenase-1, which is able to produce small amounts of eicosanoids. Extensive analysis revealed no evidence for induction of cyclooxygenase-2 in T cells. Furthermore, activated T cells up-regulate expression of cyclooxygenase-2 in both monocytes and synoviocytes. Interleukin-17 was found to be an important mediator of cyclooxygenase-2 up-regulation both directly and through synergy with tumor necrosis factor- α and interleukin-1 β . The therapeutic effects of tumor necrosis factor- α or interleukin-1 β blockade may in part be mediated by inhibition of synergy with interleukin-17. Interleukin-17 should be considered as a therapeutic target in the management of rheumatoid arthritis.

DECLARATION

This work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution, and to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text.

I give consent to this copy of my thesis, when deposited in the University Library, being available for loan and photocopying.

Signed.....

Date.....12/09/2003